MN SF4189

Commissioner of Health must conduct a comprehensive study on Minnesota's capacity for rare disease cell and gene therapy research, development, delivery, and access, in consultation with the University of Minnesota and the Minnesota Rare Disease Advisory Council

Study areas include clinical trial infrastructure, biomanufacturing capabilities, health system delivery capacity, workforce needs (clinical geneticists, gene therapy specialists), payment policies under Medical Assistance and commercial payers, and health equity barriers for rural and underserved communities

Commissioner must seek input from rare disease patients, caregivers, advocacy groups, health care providers, academic institutions, payers, pharmacy benefit managers, and biotechnology/pharmaceutical industries

Report with findings and recommendations for strategic state investments, policy changes, and federal funding opportunities due to the legislature by January 1, 2028

One-time general fund appropriation in fiscal year 2027 (amount unspecified in bill text) available until June 30, 2028